Nkarta, Inc.
NKTX
|
$7.26
-6.8%
-7.3%
730K
|
Health Technology
(0.0% 1d) (-43.8% 1m) (52.8% 1y) (0.0% 2d) (-7.3% 3d) (-16.5% 7d) (-32.46% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 511,594,921
http://www.nkartatx.com
Sec Filling | Patents | 95 employees
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
cancer t-cell treatment ceiling
add to watch list Paper trade email alert is off
Press-releases
Nkarta to Participate in Upcoming Investor Conferences
Published: 2024-04-03 (Crawled : 20:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: 2.37%
H: 4.63%
C: -3.19%
Nkarta Announces Pricing of $240 Million Underwritten Offering
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: 17.32%
H: 8.39%
C: 0.24%
million offering
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Published: 2024-03-21 (Crawled : 20:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: -22.96%
H: 11.61%
C: -10.8%
year financial results
Nkarta to Participate in Upcoming Investor Conferences
Published: 2024-02-28 (Crawled : 13:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: 2.01%
H: 0.0%
C: -6.86%
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
Published: 2023-12-10 (Crawled : 04:20) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
| Email alert
Add to watchlist
nkx101 meeting
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
Published: 2023-11-09 (Crawled : 21:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: 6.34%
H: 0.0%
C: -6.88%
financial results
Nkarta to Participate at Upcoming Investor Conferences
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -2.54%
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
Published: 2023-10-17 (Crawled : 11:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: -0.68%
H: 168.71%
C: 113.61%
nkx019 fda lupus clearance application
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: -0.68%
H: 168.71%
C: 113.61%
partnership lupus natural cell therapeutics therapy
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
Published: 2023-10-16 (Crawled : 20:00) - globenewswire.com
NKTX | $7.26 -6.8% -7.3% 730K
|
Health Technology
|
| O: -0.68%
H: 168.71%
C: 113.61%
conference pipeline expansion
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10